Schneyer Mark C. 4
4 · ACADIA PHARMACEUTICALS INC · Filed Apr 8, 2025
Insider Transaction Report
Form 4
Schneyer Mark C.
EVP, CHIEF FINANCIAL OFFICER
Transactions
- Exercise/Conversion
Restricted Stock Units
2025-04-05−5,275→ 5,276 total→ Common Stock (5,275 underlying) - Sale
Common Stock
2025-04-08$14.82/sh−2,708$40,133→ 59,456 total - Exercise/Conversion
Common Stock
2025-04-05+5,275→ 62,164 total
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
- [F3]The restricted stock units vest in four equal annual installments beginning April 5, 2023.